The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN)

Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN)
Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN)

Background: There is limited understanding on patterns of systemic treatment in adults with moderate-to-severe atopic dermatitis (AD) in the UK. Objective: To characterize treatment patterns in adult AD patients prescribed immunosuppressants (IMMs) in the primary care setting. Results: Six hundred and fifty-six patients with AD (6.6%) were prescribed IMM in the analysis (mean age 52.1 years; 59.1% female; age-adjusted Charlson comorbidity index 1.4). Most prevalent (>5%) conditions at baseline were depression (10.8%), contact dermatitis (10.7%), rheumatological disease (7.9%), skin/subcutaneous tissue disorders (6.4%), upper respiratory disease (5.8%), and psoriasis (5.2%). At baseline, up to 50% of patients were prescribed ≥1 IMM. During follow-up, 42.7% of patients were prescribed oral corticosteroids (OCSs), increasing in line with IMM exposure. The most commonly prescribed IMM was methotrexate (43.3%). Ciclosporin, the only approved IMM for AD, was prescribed to 16.9% of patients. Conclusions: The prevalence of comorbidities and high rate of IMM prescriptions demonstrate the impact of AD on quality of life. The frequency of OCS prescribing in AD patients treated with IMMs suggests a lack of disease control with existing therapies, and an unmet need for safe and effective targeted agents for long-term disease control.

Atopic dermatitis, corticosteroids, immunosuppressant, methotrexate
0954-6634
Eckert, Laurent
b2f0cad4-7e41-4327-9514-bf6ca59a9b39
Amand, Caroline
f75e4f7d-593c-42c7-b02c-697f09d86df9
Gadkari, Abhijit
4b4aa735-df51-4d49-b064-c04e3b214f29
Rout, Raj
ddff39c9-fb28-4a08-b249-114ed84e2d20
Hudson, Richard
0dbf191e-a8f1-4933-b31b-147e93d09ef9
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Eckert, Laurent
b2f0cad4-7e41-4327-9514-bf6ca59a9b39
Amand, Caroline
f75e4f7d-593c-42c7-b02c-697f09d86df9
Gadkari, Abhijit
4b4aa735-df51-4d49-b064-c04e3b214f29
Rout, Raj
ddff39c9-fb28-4a08-b249-114ed84e2d20
Hudson, Richard
0dbf191e-a8f1-4933-b31b-147e93d09ef9
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90

Eckert, Laurent, Amand, Caroline, Gadkari, Abhijit, Rout, Raj, Hudson, Richard and Ardern-Jones, Michael (2019) Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN). Journal of Dermatological Treatment. (doi:10.1080/09546634.2019.1639604).

Record type: Article

Abstract

Background: There is limited understanding on patterns of systemic treatment in adults with moderate-to-severe atopic dermatitis (AD) in the UK. Objective: To characterize treatment patterns in adult AD patients prescribed immunosuppressants (IMMs) in the primary care setting. Results: Six hundred and fifty-six patients with AD (6.6%) were prescribed IMM in the analysis (mean age 52.1 years; 59.1% female; age-adjusted Charlson comorbidity index 1.4). Most prevalent (>5%) conditions at baseline were depression (10.8%), contact dermatitis (10.7%), rheumatological disease (7.9%), skin/subcutaneous tissue disorders (6.4%), upper respiratory disease (5.8%), and psoriasis (5.2%). At baseline, up to 50% of patients were prescribed ≥1 IMM. During follow-up, 42.7% of patients were prescribed oral corticosteroids (OCSs), increasing in line with IMM exposure. The most commonly prescribed IMM was methotrexate (43.3%). Ciclosporin, the only approved IMM for AD, was prescribed to 16.9% of patients. Conclusions: The prevalence of comorbidities and high rate of IMM prescriptions demonstrate the impact of AD on quality of life. The frequency of OCS prescribing in AD patients treated with IMMs suggests a lack of disease control with existing therapies, and an unmet need for safe and effective targeted agents for long-term disease control.

Text
Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants data from The Health Improvement Network THIN - Version of Record
Download (990kB)

More information

Accepted/In Press date: 19 June 2019
e-pub ahead of print date: 15 July 2019
Keywords: Atopic dermatitis, corticosteroids, immunosuppressant, methotrexate

Identifiers

Local EPrints ID: 432860
URI: http://eprints.soton.ac.uk/id/eprint/432860
ISSN: 0954-6634
PURE UUID: d7463b94-5906-41c0-88ae-33c850d939ec

Catalogue record

Date deposited: 31 Jul 2019 16:30
Last modified: 25 Nov 2021 21:49

Export record

Altmetrics

Contributors

Author: Laurent Eckert
Author: Caroline Amand
Author: Abhijit Gadkari
Author: Raj Rout
Author: Richard Hudson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×